PEB: Positive Results in Kaiser Permanente User Programme, page-18

So there's this......



Link to article......

http://www.urologiconcology.org/art...gy.org/article/S1078-1439(17)30108-4/abstract

"The Cxbladder Monitor test significantly outperforms current Food and Drug Administration-approved urine-based monitoring tests, as well as cytology, in a large representative population undergoing surveillance for recurrent UC. This supports using Cxbladder Monitor as a confirmatory negative adjunct to cystoscopy or to justify postponing cystoscopic investigations in patients with a low risk of recurrence."

Looks like a home run to me, anyone have any bold predictions on what this could do for future royalties to CDY in $ terms?